胞外囊泡
细胞外小泡
良好制造规范
过程(计算)
可比性
质量(理念)
干细胞
翻译(生物学)
制造工艺
计算生物学
药物开发
从长凳到床边
设计质量
计算机科学
生化工程
生物技术
微泡
生物
风险分析(工程)
过程分析技术
控制(管理)
药品
化学
业务
细胞生物学
药物发现
小泡
脂泡
产品(数学)
转化研究
作者
Jiaqi Lu,Xu Gong,Jingyu Wang,Jing Dong,Xue Wang,Dongmei Han,Jing Cui,Hao Chen,Wei Wei
摘要
ABSTRACT Extracellular vesicles (EVs) have emerged as one type of the innovative medicinal products possessing low immunogenicity, cargo‐loading capacity, and potential tissue tropism. The clinical translation of stem cell‐derived EV products is advancing fast, while significant challenges exist, including complex manufacturing processes, heterogeneity in molecular composition, and diversified mechanisms of actions. The inherent variability poses obstacles for the regulatory evaluation and approval of EV products. This review provides Chemistry, Manufacturing, and Control (CMC) evaluation considerations on the stem cell‐derived EV products under drug regulatory paradigms. Specifically, critical aspects essential for Investigational New Drug (IND) applications are discussed, including the establishment of cell substrates, raw materials, manufacturing process development, viral safety, quality characterization, specification setting, stability, and comparability studies. In addition, this review summarizes the development landscape of EV products in China and globally, analyses difficulties in process and quality standardizations, and explores the translational potential and hurdles in EV products development. The aim is to provide an operational framework for EV developers from bench to bedside.
科研通智能强力驱动
Strongly Powered by AbleSci AI